# C4 Therapeutics Inc. (CCCC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.76, market value $463 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). C4 Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 13.2×**. Each dollar of revenue is priced at 13.2×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -18.5%** (5-yr avg -34.4%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -319.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -292.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -40.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -48.5%**. Return on all capital, debt included, is -48.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -28.2%**. Each dollar of assets produces -28.2% of profit.

## Growth
- **Revenue growth (1 yr): 1.0%** (3-yr 5.0%/yr). Revenue grew 1.0% over the last year.
- **EPS growth (1 yr): 16.4%**. Earnings per share rose 16.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.7×**. It would take 0.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 7.81** (quick 7.81). Current assets cover the next year's liabilities 7.81 times.
- **Altman Z-score: 3.50**. A Z-score of 3.50 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. C4 Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 40.8%** (YTD 96.9%, 3-mo -2.3%). The shares are up 40.8% over twelve months including dividends.
- **From 52-week high: -27.3%** (122.5% above the low). Trading 27% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 1.84** (volatility 90%). Beta of 1.84 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CCCC · Page: https://foliofundamentals.com/stocks/cccc

Not investment advice.